Department of Endocrinology, Post Graduate Institute of Medical Education and Research, Chandigarh, 160012, India.
Department of Biomedical Informatics, Emory School of Medicine, Atlanta, GA-30322, United States.
Infect Disord Drug Targets. 2021;21(5):e270421186842. doi: 10.2174/1871526520666201013160803.
The novel coronavirus disease (COVID-19) is on the rampage claiming over 297000 lives globally. Disease severity and mortality rates are higher in patients with underlying diabetes mellitus. Till date, there exists no effective vaccine or therapy against COVID-19. However, with limited clinical data, HCQ is being used for treatment and prophylaxis in patients with COVID-19. HCQ is also used as an anti-diabetic drug and has been approved in India as an adjunct to diet and exercise to improve glycemic control of patients with Type 2 Diabetes Mellitus (T2DM) on metformin and sulfonylurea combination in Type 2 Diabetes Mellitus (T2DM). Thus, although indiscriminate use of HCQ is fraught with danger, HCQ can be considered as a third-line add on anti-diabetic agent in people with T2DM amid the ongoing pandemic after having ruled out the contraindications to the use of this drug.
新型冠状病毒病（COVID-19）正在肆虐，全球已有超过 297000 人死亡。患有基础糖尿病的患者病情严重程度和死亡率更高。迄今为止，尚无针对 COVID-19 的有效疫苗或疗法。然而，根据有限的临床数据，HCQ 被用于 COVID-19 患者的治疗和预防。HCQ 也被用作一种抗糖尿病药物，在印度已被批准作为饮食和运动的辅助手段，以改善二甲双胍和磺脲类联合治疗的 2 型糖尿病（T2DM）患者的血糖控制，以及在 2 型糖尿病（T2DM）患者中添加到治疗方案中。因此，尽管 HCQ 的盲目使用存在危险，但在当前大流行期间，如果排除了使用该药的禁忌症，HCQ 可以被认为是 T2DM 患者的三线附加抗糖尿病药物。
